New FDA Cybersecurity Requirements for Medical Devices

On March 29th, 2023, new legislation was signed into law which means that all medical cyber devices must meet certain cybersecurity standards. Adjust to these new standards by integrating with SelectEvidence

 

As Seen In

New Cybersecurity Requirements for Cyber Medical Devices

The way that medical device manufacturers prepare premarket submissions underwent a significant change in 2023 which has impacted how cybersecurity is incorporated into the entire medical device lifecycle.  

 

This change came as a result of the Consolidated Appropriations Act (Omnibus Bill) which was signed into law on the 29th of December 2022, and came into effect 90 days later on the 29th of March 2023. 
To comply with new FDA cybersecurity requirements, medical device manufacturers must monitor and address vulnerabilities, submit an SBOM and provide regular updates and patch plans to ensure device safety. 

The most frequently asked questions about the new FDA cybersecurity requirements for medical devices

learn more

What Are the Four New FDA Cybersecurity Requirements for Medical Devices?

1.  Postmarket Monitoring: Submit a plan to monitor, identify, and address, postmarket cybersecurity vulnerabilities and exploits, including coordinated vulnerability disclosure and related procedures; 
2. Device Updates: Design, develop, and maintain processes and procedures to provide a reasonable assurance that the device and related systems are cybersecure, and make available postmarket updates and patches to the device and related systems to address— on a reasonably justified regular cycle, known unacceptable vulnerabilities; and as soon as possible out of cycle, critical vulnerabilities that could cause uncontrolled risks;
3. SBOM: Provide a software bill of materials (SBOM)
4. Regulatory Compliance: Ensure compliance with other requirements that the FDA may require through regulation to demonstrate reasonable assurance that the device and related systems are cyber secure.
Learn More
New Cybersecurity Requirements for Medical Devices

How SelectEvidence™ Enables You Meet New FDA Cybersecurity Requirements 

  1. Postmarket Monitoring: SelectEvidence™ allows you to automate postmarket cybersecurity monitoring. You can also automate the performance of premarket cybersecurity risk assessments and generate all regulatory and customer reports.
  2. Device Updates: Manage traceability and revision control throughout the medical device lifecycle. 
  3. SBOM: Multi-format ingestion of each and every Software Bill of Materials.
  4. Regulatory Compliance: With SelectEvidence™ you can reuse mitigation knowhow across your portfolio of risk assessments. This enhances standardization and reduces duplicate analysis.

Selectevidence™

Sign up for a free, zero-obligation demo today.

Sign up today

FDA’s Refuse-to-Accept Policy

Alongside these new security requirements is FDA’s new RTA policy (refuse-to-accept policy). 
This policy, which came into effect in October 2023, means that FDA will reject or ‘refuse to accept’ submissions that do not include information relating to the four new FDA cybersecurity requirements for medical devices.

Meet New Cybersecurity Requirements By Integrating With SelectEvidence™ 

Medical device manufacturers can meet the new FDA cybersecurity requirements by integrating with SelectEvidence™. 
SelectEvidence™ is a cybersecurity risk management solution for connected medical devices that automates the continuous monitoring of vulnerabilities and the identification of related mitigations, while generating live regulatory reports. 
Sign up today

Sign Up For a Demo Today

By clicking 'submit', you agree to our Terms & Conditions.

About Nova Leah

Nova Leah is a world leader in the provision of cybersecurity risk management solutions for medical device manufacturers and healthcare providers.

Join our team: We Are Hiring!

Site Links

Home
SelectEvidence™
SelectEvaluate® for Manufacturers

SelectEvaluate® for Healthcare
About
News
Legal
Contact

Sign Up to our newsletter
Irish Office

P: +353 42 93 43 0 33

Block 3, Finnabair Business &
Technology Park, Dundalk, Co Louth, Ireland A91 XR61

US Office

P: +1 617 314 7010

6th Floor, 399 Boylston Street,
Boston, MA 02116,
United States

Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google